الانتقال إلى المحتوى الرئيسي
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

المرحلة 2مطلوب 360 مشاركاً22 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

الحالات

  • Overweight or Obesity

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 2
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةQUADRUPLE (4)
التجنيدمطلوب 360 مشاركاً

الجهة الراعية والمتعاونون

  • Regeneron Pharmaceuticals الجهة الراعية

الأذرع والتدخلات

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

التدخلات

  • دواء Olatorepatide

    Administered per the protocol

  • دواء Placebo

    Administered per the protocol

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    الإطار الزمني Up to approximately 60 weeks

  2. مقياس النتيجة الأولي

    Severity of TEAEs

    الإطار الزمني Up to approximately 60 weeks

  3. مقياس النتيجة الأولي

    Percent change in body weight

    الإطار الزمني From baseline to week 52

  4. مقياس النتيجة الثانوي

    Olatorepatide concentrations

    الإطار الزمني Up to approximately 60 weeks

  5. مقياس النتيجة الثانوي

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    الإطار الزمني Up to approximately 52 weeks

  6. مقياس النتيجة الثانوي

    Magnitude of ADA to olatorepatide

    الإطار الزمني Up to approximately 52 weeks

التواريخ

التواريخ
تاريخ البدء28 يوليو 2026 (فعلي)
الإتمام الأولي21 يناير 2028 (تقديري)
الإتمام21 يناير 2028 (تقديري)
أول نشر6 يوليو 2026 (فعلي)
آخر تحديث18 نوفمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةنوفمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

22 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Flourish Research, Ravenswood RheumatologyChicagoIllinoisقيد التجنيد
Charter Research LLC - ChicagoChicagoIllinoisقيد التجنيد
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaقيد التجنيد
AMR Clinical - Fort MyersFort MyersFloridaقيد التجنيد
Tribe Clinical ResearchGreenvilleSouth Carolinaقيد التجنيد
AGA Clinical TrialsHialeahFloridaقيد التجنيد
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaقيد التجنيد
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaقيد التجنيد
AMR Clinical - LexingtonLexingtonKentuckyقيد التجنيد
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaقيد التجنيد
AMR Clinical - MobileMobileAlabamaقيد التجنيد
NYC Research IncNew YorkNew Yorkقيد التجنيد
AMR Clinical - Chicago Oak BrookOak BrookIllinoisقيد التجنيد
Velocity Clinical Research - OmahaOmahaNebraskaقيد التجنيد
Rochester Clinical ResearchRochesterNew Yorkقيد التجنيد
Flourish Research, Legacy Oaks TowerSan AntonioTexasقيد التجنيد
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaقيد التجنيد
Charter Research LLC - The VillagesThe VillagesFloridaقيد التجنيد
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaقيد التجنيد
Chase Medical ResearchWaterburyConnecticutقيد التجنيد
AMR Clinical WichitaWichitaKansasقيد التجنيد
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 18 نوفمبر 2026

    أُضيف موقع

    1 site added (22 total)

    2122

  2. 13 أكتوبر 2026

    أُضيف موقع

    3 sites added (21 total)

    1821

  3. 29 سبتمبر 2026

    أُضيف موقع

    13 sites added (18 total)

    518

  4. 20 أغسطس 2026

    تغيّرت الحالة

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20 أغسطس 2026

    فُتح التجنيد

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20 أغسطس 2026

    أُضيف موقع

    5 sites added (5 total)

    05